{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:11:25Z","timestamp":1789139485273,"version":"build-2803163510"},"posted":{"date-parts":[[2026,9,11]]},"group-title":"In Review","reference-count":0,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,8,28]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Background\n                  <italic>CYLD<\/italic>\n                  , a tumor suppressor gene encoding a deubiquitinase enzyme, regulates tumorigenesis via NF-\u03baB signaling.\n                  <italic>CYLD<\/italic>\n                  mutations are linked to immune evasion and PD-L1 upregulation, particularly in virus-associated cancers. We evaluated\n                  <italic>CYLD<\/italic>\n                  alterations across cancers and their correlation with PD-L1 expression. Given the established link between\n                  <italic>CYLD<\/italic>\n                  dysfunction and viral oncogenesis, we also assessed the co-occurrence of\n                  <italic>CYLD<\/italic>\n                  alterations and human papillomavirus (HPV) status.\nMethods\n We conducted a real-world data analysis of\n                  <italic>CYLD<\/italic>\n                  alterations in 145,991 tumor samples that underwent clinical-grade comprehensive genomic profiling during routine care; PD-L1 expression via immunohistochemistry (IHC) was assessed in 10,053 specimens. The relationship between\n                  <italic>CYLD<\/italic>\n                  alterations and high-risk HPV across cancers was also evaluated.\nResults\n                  <italic>CYLD<\/italic>\n                  mutations occurred in 0.57% (836\/145,991) of tumors, with the highest rates in thymic carcinomas (15.4%, 34\/220), anal carcinomas (11.4%, 55\/479), and head and neck cancers (6.4%, 154\/2,423). Among 10,053 samples with PD-L1 IHC evaluated, 62 (0.6%) harbored\n                  <italic>CYLD<\/italic>\n                  alterations. Overall, 61% (38\/62) of\n                  <italic>CYLD<\/italic>\n                  -altered tumors were positive for PD-L1 IHC expression (\u2265\u20091%), with 29% (18\/62) exhibiting high PD-L1 expression (\u2265\u200950%). In addition, 27.5% (230\/836) of\n                  <italic>CYLD<\/italic>\n                  -altered tumors were HPV+, with strong enrichment in head and neck cancers (odds ratio [OR]\u2009=\u20097.4; p\u2009&lt;\u20090.0001).\nConclusions\n We highlight the rarity of\n                  <italic>CYLD<\/italic>\n                  mutations across most cancers but underscore their relatively elevated prevalence in thymic carcinomas, anal carcinomas, and head and neck cancers. The observed associations between\n                  <italic>CYLD<\/italic>\n                  alterations, PD-L1 expression, and HPV positivity suggest that\n                  <italic>CYLD<\/italic>\n                  status, combined with immune and viral biomarkers, may merit exploration as a predictor of immunotherapy benefits.\n                <\/p>","DOI":"10.21203\/rs.3.rs-10854026\/v1","type":"posted-content","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:21:51Z","timestamp":1789136511000},"source":"Crossref","is-referenced-by-count":0,"title":["CYLD Mutations, PD-L1 and HPV; A Pan-Cancer Landscape Analysis"],"prefix":"10.21203","author":[{"given":"Umut","family":"Di\u015fel","sequence":"first","affiliation":[{"name":"Ac\u0131badem Adana Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya Dushyant","family":"Sisoudiya","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smruthy","family":"Sivakumar","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10854026\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10854026\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:21:57Z","timestamp":1789136517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10854026\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-10854026\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,9,11]]},"subtype":"preprint"}}